Annual Total Long Term Liabilities
$364.60 M
+$241.40 M+195.94%
31 December 2023
Summary:
Neurocrine Biosciences annual total long term liabilities is currently $364.60 million, with the most recent change of +$241.40 million (+195.94%) on 31 December 2023. During the last 3 years, it has fallen by -$88.10 million (-19.46%). NBIX annual total long term liabilities is now -19.46% below its all-time high of $452.70 million, reached on 31 December 2021.NBIX Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
Quarterly Long Term Liabilities
$386.40 M
-$10.90 M-2.74%
30 September 2024
Summary:
Neurocrine Biosciences quarterly total long term liabilities is currently $386.40 million, with the most recent change of -$10.90 million (-2.74%) on 30 September 2024. Over the past year, it has increased by +$21.80 million (+5.98%). NBIX quarterly long term liabilities is now -25.88% below its all-time high of $521.30 million, reached on 31 March 2020.NBIX Quarterly Long Term Liabilities Chart
Add series to chart(max: 6)
company, ETF, index, featured screener or watchlist
NBIX Long Term Liabilities Performance
| PeriodPeriod | AnnualAnnual | QuarterlyQuarterly |
|---|---|---|
| 1 y1 year | - | +6.0% |
| 3 y3 years | -19.5% | -14.7% |
| 5 y5 years | +251.3% | +272.3% |
NBIX Long Term Liabilities High & Low
| PeriodPeriod | Annual vs highAnnual vs high | Annual vs lowAnnual vs low | Quarter. vs highQuarter. vs high | Quarter. vs lowQuarter. vs low | |
|---|---|---|---|---|---|
| 3 y | 3 years | -19.5% | +195.9% | -22.7% | +239.8% |
| 5 y | 5 years | -19.5% | +251.3% | -25.9% | +342.6% |
| alltime | all time | -19.5% | >+9999.0% | -25.9% | >+9999.0% |
Neurocrine Biosciences Long Term Liabilities History
| Date | Annual | Quarterly |
|---|---|---|
| Sept 2024 | - | $386.40 M(-2.7%) |
| June 2024 | - | $397.30 M(+6.4%) |
| Mar 2024 | - | $373.40 M(+2.4%) |
| Dec 2023 | $364.60 M(+195.9%) | $364.60 M(+136.0%) |
| Sept 2023 | - | $154.50 M(-13.0%) |
| June 2023 | - | $177.60 M(-41.0%) |
| Mar 2023 | - | $301.20 M(+144.5%) |
| Dec 2022 | $123.20 M(-72.8%) | $123.20 M(+8.4%) |
| Sept 2022 | - | $113.70 M(-61.7%) |
| June 2022 | - | $296.60 M(-40.7%) |
| Mar 2022 | - | $499.90 M(+10.4%) |
| Dec 2021 | $452.70 M(+7.3%) | $452.70 M(+1.6%) |
| Sept 2021 | - | $445.40 M(-4.1%) |
| June 2021 | - | $464.30 M(+3.0%) |
| Mar 2021 | - | $450.80 M(+6.8%) |
| Dec 2020 | $422.00 M(+306.6%) | $422.00 M(+383.4%) |
| Sept 2020 | - | $87.30 M(-21.6%) |
| June 2020 | - | $111.40 M(-78.6%) |
| Mar 2020 | - | $521.30 M(+402.2%) |
| Dec 2019 | $103.80 M(-75.5%) | $103.80 M(-78.8%) |
| Sept 2019 | - | $489.77 M(+1.5%) |
| June 2019 | - | $482.57 M(+1.3%) |
| Mar 2019 | - | $476.44 M(+12.3%) |
| Dec 2018 | $424.15 M(+8.5%) | $424.15 M(+1321.8%) |
| Sept 2018 | - | $29.83 M(-92.6%) |
| June 2018 | - | $402.12 M(+1.7%) |
| Mar 2018 | - | $395.41 M(+1.1%) |
| Dec 2017 | $391.03 M(+1875.4%) | $391.03 M(+1.1%) |
| Sept 2017 | - | $386.84 M(+1.5%) |
| June 2017 | - | $381.13 M(+1942.5%) |
| Mar 2017 | - | $18.66 M(-5.7%) |
| Dec 2016 | $19.80 M(-19.6%) | $19.80 M(-5.0%) |
| Sept 2016 | - | $20.84 M(-4.8%) |
| June 2016 | - | $21.90 M(-5.2%) |
| Mar 2016 | - | $23.10 M(-6.2%) |
| Dec 2015 | $24.62 M(+31.8%) | $24.62 M(-4.1%) |
| Sept 2015 | - | $25.67 M(-3.9%) |
| June 2015 | - | $26.71 M(-4.1%) |
| Mar 2015 | - | $27.86 M(+49.2%) |
| Dec 2014 | $18.67 M(-17.3%) | $18.67 M(-5.1%) |
| Sept 2014 | - | $19.67 M(-4.7%) |
| June 2014 | - | $20.64 M(-4.6%) |
| Mar 2014 | - | $21.63 M(-4.1%) |
| Dec 2013 | $22.57 M(-13.1%) | $22.57 M(-3.4%) |
| Sept 2013 | - | $23.35 M(-3.6%) |
| June 2013 | - | $24.22 M(-3.5%) |
| Mar 2013 | - | $25.09 M(-3.3%) |
| Dec 2012 | $25.96 M(-16.7%) | $25.96 M(-3.2%) |
| Sept 2012 | - | $26.83 M(-4.9%) |
| June 2012 | - | $28.20 M(-5.0%) |
| Mar 2012 | - | $29.68 M(-4.8%) |
| Dec 2011 | $31.18 M(-56.9%) | $31.18 M(-27.2%) |
| Sept 2011 | - | $42.84 M(-17.4%) |
| June 2011 | - | $51.86 M(-16.3%) |
| Mar 2011 | - | $61.98 M(-14.3%) |
| Dec 2010 | $72.30 M | $72.30 M(-9.7%) |
| Sept 2010 | - | $80.10 M(-11.5%) |
| Date | Annual | Quarterly |
|---|---|---|
| June 2010 | - | $90.51 M(+103.2%) |
| Mar 2010 | - | $44.53 M(-5.1%) |
| Dec 2009 | $46.90 M(-15.2%) | $46.90 M(-7.7%) |
| Sept 2009 | - | $50.79 M(+9.2%) |
| June 2009 | - | $46.50 M(-5.8%) |
| Mar 2009 | - | $49.38 M(-10.7%) |
| Dec 2008 | $55.31 M(-56.8%) | $55.31 M(-55.8%) |
| Sept 2008 | - | $125.11 M(-1.0%) |
| June 2008 | - | $126.33 M(-0.7%) |
| Mar 2008 | - | $127.25 M(-0.6%) |
| Dec 2007 | $128.05 M(+133.5%) | $128.05 M(+143.8%) |
| Sept 2007 | - | $52.52 M(-2.5%) |
| June 2007 | - | $53.87 M(-0.6%) |
| Mar 2007 | - | $54.19 M(-1.2%) |
| Dec 2006 | $54.84 M(-7.6%) | $54.84 M(-2.7%) |
| Sept 2006 | - | $56.39 M(-0.8%) |
| June 2006 | - | $56.84 M(-6.5%) |
| Mar 2006 | - | $60.82 M(+2.5%) |
| Dec 2005 | $59.33 M(-9.8%) | $59.33 M(-4.6%) |
| Sept 2005 | - | $62.19 M(-1.6%) |
| June 2005 | - | $63.20 M(-2.0%) |
| Mar 2005 | - | $64.47 M(-2.0%) |
| Dec 2004 | $65.81 M(+22.3%) | $65.81 M(-3.1%) |
| Sept 2004 | - | $67.94 M(+0.8%) |
| June 2004 | - | $67.44 M(+24.1%) |
| Mar 2004 | - | $54.33 M(+0.9%) |
| Dec 2003 | $53.82 M(+448.9%) | $53.82 M(+7.0%) |
| Sept 2003 | - | $50.30 M(-17.8%) |
| June 2003 | - | $61.18 M(+20.6%) |
| Mar 2003 | - | $50.75 M(+417.5%) |
| Dec 2002 | $9.81 M(-12.4%) | $9.81 M(+6.5%) |
| Sept 2002 | - | $9.20 M(-12.4%) |
| June 2002 | - | $10.51 M(-1.8%) |
| Mar 2002 | - | $10.70 M(-4.5%) |
| Dec 2001 | $11.20 M(+43.6%) | $11.20 M(+11.8%) |
| Sept 2001 | - | $10.01 M(+26.5%) |
| June 2001 | - | $7.91 M(+6.2%) |
| Mar 2001 | - | $7.45 M(-4.4%) |
| Dec 2000 | $7.79 M(+85.6%) | $7.79 M(+75.2%) |
| Sept 2000 | - | $4.45 M(+11.7%) |
| June 2000 | - | $3.98 M(-10.2%) |
| Mar 2000 | - | $4.43 M(+5.5%) |
| Dec 1999 | $4.20 M(+44.8%) | $4.20 M(+5.0%) |
| Sept 1999 | - | $4.00 M(+11.1%) |
| June 1999 | - | $3.60 M(+24.1%) |
| Mar 1999 | - | $2.90 M(0.0%) |
| Dec 1998 | $2.90 M(+70.6%) | $2.90 M(-6.5%) |
| Sept 1998 | - | $3.10 M(+82.4%) |
| June 1998 | - | $1.70 M(+30.8%) |
| Mar 1998 | - | $1.30 M(-23.5%) |
| Dec 1997 | $1.70 M(+54.5%) | $1.70 M(+54.5%) |
| Sept 1997 | - | $1.10 M(0.0%) |
| June 1997 | - | $1.10 M(-8.3%) |
| Mar 1997 | - | $1.20 M(+9.1%) |
| Dec 1996 | $1.10 M | $1.10 M(-15.4%) |
| Sept 1996 | - | $1.30 M(-13.3%) |
| June 1996 | - | $1.50 M(-11.8%) |
| Mar 1996 | - | $1.70 M |
FAQ
- What is Neurocrine Biosciences annual total long term liabilities?
- What is the all time high annual total long term liabilities for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly total long term liabilities?
- What is the all time high quarterly long term liabilities for Neurocrine Biosciences?
- What is Neurocrine Biosciences quarterly long term liabilities year-on-year change?
What is Neurocrine Biosciences annual total long term liabilities?
The current annual total long term liabilities of NBIX is $364.60 M
What is the all time high annual total long term liabilities for Neurocrine Biosciences?
Neurocrine Biosciences all-time high annual total long term liabilities is $452.70 M
What is Neurocrine Biosciences quarterly total long term liabilities?
The current quarterly long term liabilities of NBIX is $386.40 M
What is the all time high quarterly long term liabilities for Neurocrine Biosciences?
Neurocrine Biosciences all-time high quarterly total long term liabilities is $521.30 M
What is Neurocrine Biosciences quarterly long term liabilities year-on-year change?
Over the past year, NBIX quarterly total long term liabilities has changed by +$21.80 M (+5.98%)